eli lilly tirzepatide news today recency 3 says weight loss drug cuts heart failure risk by 38% in trial FDA Approves Lilly's Zepbound™ (tirzepatide)

According to the UK Summary of Product Characteristics (SmPC), these include: Nausea (very common: may affect more than 1 in 10 people) Diarrhoea (very common) Vomiting (very common) Constipation (very common) Abdominal pain and dyspepsia (common) These gastrointestinal effects typically diminish over time as the body adjusts to the medication

Captured also patients out of treatment

Slower Gastric Emptying Semaglutide also slows the rate at which food leaves your stomach, contributing to longer-lasting feelings of fullness

Compound class: synthetic small oligopeptide

Ledinek AH, Sajko MC, Rot U

The Tirzepatide Advantage: * Dual Action Mechanism: Tirzepatide's unique dual GIP and GLP-1 receptor agonism sets it apart, providing a synergistic effect for enhanced weight loss